{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T02:55:27Z","timestamp":1771296927647,"version":"3.50.1"},"reference-count":184,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T00:00:00Z","timestamp":1623369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.tranon.2021.101153","type":"journal-article","created":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T14:07:20Z","timestamp":1623766040000},"page":"101153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Hepatocellular cancer therapy in patients with HIV infection: Disparities in cancer care, trials enrolment, and cancer-related research"],"prefix":"10.1016","volume":"14","author":[{"given":"Francesca","family":"Negri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Missale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Degli","family":"Antoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camillo","family":"Porta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2021.101153_bib0001","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2021.101153_bib0002","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.1073\/pnas.92.11.4838","article-title":"Tat, the human immunodeficiency virus type regulatory protein, has angiogenic properties","volume":"92","author":"Albini","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.tranon.2021.101153_bib0003","first-page":"259","article-title":"Comparative dosing and efficacy of sorafenib in hepatocellular cancer patients with varying liver dysfunction","volume":"6","author":"Al-Rajabi","year":"2015","journal-title":"J. Gastrointest. Oncol."},{"key":"10.1016\/j.tranon.2021.101153_bib0004","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0002-9440(10)64622-6","article-title":"Enhancement of chemical hepatocarcinogenesis by the HIV-1 tat gene","volume":"157","author":"Altavilla","year":"2000","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.tranon.2021.101153_bib0005","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.4049\/jimmunol.168.7.3660","article-title":"Dynamics of T cell responses in HIV infection","volume":"168","author":"Appay","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.tranon.2021.101153_bib0006","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nature04444","article-title":"Restoring function in exhausted CD8 T cells during chronic viral infection","volume":"439","author":"Barber","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.tranon.2021.101153_bib0007","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000947","article-title":"Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation","volume":"6","author":"Bengsch","year":"2010","journal-title":"PLOS Pathog"},{"key":"10.1016\/j.tranon.2021.101153_bib0008","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.jhep.2014.07.005","article-title":"Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation","volume":"61","author":"Bengsch","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tranon.2021.101153_bib0009","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jim.2017.03.009","article-title":"Deep immune profiling by mass cytometry links human T and NK cell differentiation and cytotoxic molecule expression patterns","volume":"453","author":"Bengsch","year":"2018","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.tranon.2021.101153_bib0010","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1634\/theoncologist.2010-0400","article-title":"Hepatocellular carcinoma in HIV-infected patients: check early, treat hard","volume":"16","author":"Berretta","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.tranon.2021.101153_bib0011","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/CAD.0b013e32835c032f","article-title":"Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients","volume":"24","author":"Berretta","year":"2013","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.tranon.2021.101153_bib0012","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jama.300.1.51","article-title":"Changes in the risk of death after HIV seroconversion compared with mortality in the general population","volume":"300","author":"Bhaskaran","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.tranon.2021.101153_bib0013","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1086\/318501","article-title":"Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection","volume":"32","author":"Bica","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tranon.2021.101153_bib0014","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/ni.1679","article-title":"Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection","volume":"10","author":"Blackburn","year":"2009","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.tranon.2021.101153_bib0015","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/0008-5472.CAN-03-3259","article-title":"PD-L1\/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells","volume":"64","author":"Blank","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.tranon.2021.101153_bib0016","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/cncr.20354","article-title":"Malignancy-related causes of death in human immunodeficiency virus infected patients in the era of highly active antiretroviral therapy","volume":"101","author":"Bonnet","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.tranon.2021.101153_bib0017","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.clinre.2011.11.002","article-title":"Primary liver cancer is more aggressive in HIV-HCV coinfection than in HCV infection. A prospective study (ANRS CO13 Hepavih and CO12 Cirvir)","volume":"36","author":"Bourcier","year":"2012","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"10.1016\/j.tranon.2021.101153_bib0018","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jhep.2005.07.006","article-title":"Slower fibrosis progression in HIV\/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy","volume":"44","author":"Brau","year":"2006","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tranon.2021.101153_bib0019","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jhep.2007.06.010","article-title":"Presentation and outcome of hepatocellular carcinoma in HIV infected patients: a U.S.-Canadian multicenter study","volume":"47","author":"Brau","year":"2007","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tranon.2021.101153_bib0020","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.tranon.2021.101153_bib0021","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jhep.2012.06.014","article-title":"Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial","volume":"57","author":"Bruix","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tranon.2021.101153_bib0022","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.tranon.2021.101153_bib0023","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1086\/605594","article-title":"Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort","volume":"49","author":"Bruyand","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tranon.2021.101153_bib0024","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.immuni.2016.04.023","volume":"44","author":"Callahan","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.tranon.2021.101153_bib0025","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1089\/aid.1995.11.1039","article-title":"HIV type 1 extracellular Tat protein stimulates growth and protects cells of BK virus\/tat transgenic mice from apoptosis","volume":"11","author":"Campioni","year":"1995","journal-title":"AIDS. Res. Hum. Retroviruses."},{"key":"10.1016\/j.tranon.2021.101153_bib0026","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00280-006-0393-4","article-title":"Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models","volume":"59","author":"Chang","year":"2007","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"Suppl 1","key":"10.1016\/j.tranon.2021.101153_bib0027","first-page":"S165","article-title":"Complete response after sorafenib therapy for hepatocellular carcinoma in an HIV-HBV co-infected patient: possible synergy with HAART?","volume":"28","author":"Chelis","year":"2011","journal-title":"A case report. Med. Oncol."},{"key":"10.1016\/j.tranon.2021.101153_bib0028","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tranon.2021.101153_bib0029","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jhep.2016.06.019","article-title":"Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis","volume":"65","author":"Cheung","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tranon.2021.101153_bib0030","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev.iy.13.040195.000333","article-title":"Hepatitis B virus immunopathogenesis","volume":"13","author":"Chisari","year":"1995","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.tranon.2021.101153_bib0031","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1097\/QAD.0b013e32831103ad","article-title":"Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma","volume":"22","author":"Clifford","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.tranon.2021.101153_bib0032","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jhep.2016.06.015","article-title":"Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals","volume":"65","author":"Conti","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tranon.2021.101153_bib0033","first-page":"5569","article-title":"Systemic expression of HIV-1 tat gene in transgenic mice induces endothelial proliferation and tumors of different histotypes.","volume":"53","author":"Corallini","year":"1993","journal-title":"Cancer. Res."},{"key":"10.1016\/j.tranon.2021.101153_bib0034","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/nm863","article-title":"Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity","volume":"9","author":"Curiel","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.tranon.2021.101153_bib0035","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.2217\/fon.15.163","article-title":"Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study.","volume":"11","author":"Daniele","year":"2015","journal-title":"Future Oncol"},{"key":"10.1016\/j.tranon.2021.101153_bib0036","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1084\/jem.20031947","article-title":"Progress in defining CD4 helper cell responses in chronic viral infections","volume":"198","author":"Day","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.tranon.2021.101153_bib0037","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature05115","article-title":"PD-1 expression on HIV specific T cells is associated with T-cell exhaustion and disease progression","volume":"443","author":"Day","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.tranon.2021.101153_bib0038","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nm.4108","article-title":"International AIDS society towards a cure working group. International AIDS Society global scientific strategy: towards an HIV cure 2016","volume":"22","author":"Deeks","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.tranon.2021.101153_bib0039","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1002\/hep.27005","article-title":"GATA4 loss in the septum transversum mesenchyme promotes liver fibrosis in mice","volume":"59","author":"Delgado","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.tranon.2021.101153_bib0040","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.3892\/or.2015.3816","article-title":"Ribavirin as a tri-targeted antitumor repositioned drug","volume":"33","author":"De la Cruz-Hernandez","year":"2015","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.tranon.2021.101153_bib0041","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1128\/jvi.70.7.4427-4437.1996","article-title":"Activation of transcription factor NF-Kb by the tat protein of human immunodeficiency virus type-1","volume":"70","author":"De Marchi","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/j.tranon.2021.101153_bib0042","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1750-9378-7-15","article-title":"Treatment of recurrent hepatocellular carcinoma with sorafenib in a HIV\/HCV co-infected patient in HAART: a case report","volume":"7","author":"De Nardo","year":"2012","journal-title":"Infect. Agent cancer"},{"key":"10.1016\/j.tranon.2021.101153_bib0043","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/COH.0000000000000335","article-title":"Hepatocellular carcinoma in patients with HIV","volume":"12","author":"Dika","year":"2017","journal-title":"Curr. Opin. HIV. AIDS."},{"key":"10.1016\/j.tranon.2021.101153_bib0044","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3816\/CLC.2010.n.051","article-title":"Human immunodeficiency virus-associated primary lung cancer in the era of highly active antiretroviral therapy: a multi-institutional collaboration","volume":"11","author":"D'Jaen","year":"2010","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.tranon.2021.101153_bib0045","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.immuni.2012.08.021","article-title":"Network analysis reveals centrally connected genes and pathways involved in CD8+ T cell exhaustion versus memory","volume":"37","author":"Doering","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.tranon.2021.101153_bib0046","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.tranon.2021.101153_bib0047","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.4049\/jimmunol.179.3.1979","article-title":"Programmed death 1 expression on HIV-specific CD4+T cells is driven by viral replication and associated with T cell dysfunction","volume":"179","author":"D'Souza","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.tranon.2021.101153_bib0048","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1182\/blood-2009-11-253039","article-title":"The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma","volume":"115","author":"Dunleavy","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2021.101153_bib0049","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa1308392","article-title":"Low-intensity therapy in adults with Burkitt's lymphoma","volume":"369","author":"Dunleavy","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2021.101153_bib0050","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3343\/alm.2012.32.2.113","article-title":"Relationship of oxidative stress in hepatitis B infection activity with HBV DNA and fibrosis","volume":"32","author":"Duygu","year":"2012","journal-title":"Ann. Lab. Med."},{"key":"10.1016\/j.tranon.2021.101153_bib0051","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.tranon.2021.101153_bib0052","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/345084a0","article-title":"Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients","volume":"345","author":"Ensoli","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.tranon.2021.101153_bib0053","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/371674a0","article-title":"Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma","volume":"371","author":"Ensoli","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.tranon.2021.101153_bib0054","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1158\/1078-0432.CCR-05-2188","article-title":"Evaluation of antitumoral properties of the protease inhibitor indinavir in a murine model of hepatocarcinoma","volume":"12","author":"Esposito","year":"2006","journal-title":"Clin Cancer. Res."},{"key":"10.1016\/j.tranon.2021.101153_bib0055","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s13238-013-2084-3","article-title":"NF-kappaB and STAT3 signaling pathways collaboratively link inflammation to cancer","volume":"4","author":"Fan","year":"2013","journal-title":"Protein Cell"},{"key":"10.1016\/j.tranon.2021.101153_bib0056","first-page":"311","article-title":"world gastroenterology organisation guidelines and publication committee. World gastroenterology organisation guideline (HCC): a global perspective","volume":"19","author":"Ferenci","year":"2010","journal-title":"J. Gastrointestin. Liver. Dis."},{"key":"10.1016\/j.tranon.2021.101153_bib0057","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2021.101153_bib0058","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.tranon.2021.101153_bib0059","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/liv.13921","article-title":"Prognostic factors of survival in HIV\/HCV co-infected patients with hepatocellular carcinoma: the CARCINOVIC Cohort","volume":"39","author":"Gelu-Simeon","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.tranon.2021.101153_bib0060","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1001\/archinte.164.21.2349","article-title":"Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992-2001","volume":"164","author":"Giordano","year":"2004","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.tranon.2021.101153_bib0061","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.dld.2012.12.010","article-title":"Outcome of hepatocellular carcinoma in human immunodeficiency virus-infected patients","volume":"45","author":"Gramenzi","year":"2013","journal-title":"Dig. Liver. Dis."},{"key":"10.1016\/j.tranon.2021.101153_bib0062","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1146\/annurev.immunol.23.021704.115611","article-title":"The B7 family revisited","volume":"23","author":"Greenwald","year":"2005","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.tranon.2021.101153_bib0063","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2174\/157488708783330549","article-title":"Immunotherapy of HCC","volume":"3","author":"Greten","year":"2008","journal-title":"Rev. Recent. Clin. Trials"},{"key":"10.1016\/j.tranon.2021.101153_bib0064","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/annonc\/mdx696","article-title":"Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer","volume":"29","author":"Guihot","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tranon.2021.101153_bib0065","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1093\/annonc\/mdx538","article-title":"Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patients","volume":"28","author":"Heppt","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tranon.2021.101153_bib0066","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1158\/0008-5472.1089.65.3","article-title":"Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity","volume":"65","author":"Hirano","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.tranon.2021.101153_bib0067","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S0168-8278(05)80579-3","article-title":"Presence of HIV-1 in human parenchymal and nonparenchymal liver cells in vivo","volume":"19","author":"Housset","year":"1993","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tranon.2021.101153_bib0068","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/hep.25800","article-title":"The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection","volume":"57","author":"Ioannou","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.tranon.2021.101153_bib0069","doi-asserted-by":"crossref","first-page":"16319","DOI":"10.1073\/pnas.252530499","article-title":"A pectin glucuronyltransferase gene is essential for intercellular attachment in the plant meristem","volume":"99","author":"Iwai","year":"2002","journal-title":"PNAS"},{"key":"10.1016\/j.tranon.2021.101153_bib0070","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/intimm\/dxh194","article-title":"PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells","volume":"17","author":"Iwai","year":"2005","journal-title":"Int. Immunol."},{"key":"10.1016\/j.tranon.2021.101153_bib0071","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1200\/JCO.2016.69.5197","article-title":"Impact of viral status on survival in patients receiving sorafenib for advanced hepatocellular cancer: a meta-analysis of randomized phase III trials","volume":"35","author":"Jackson","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2021.101153_bib0072","doi-asserted-by":"crossref","first-page":"v59","DOI":"10.1093\/annonc\/mdq166","article-title":"ESMO Guidelines Working Group. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Jelic","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tranon.2021.101153_bib0073","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/S0140-6736(10)62001-6","article-title":"Increasing burden of liver disease in patients with HIV infection","volume":"377","author":"Joshi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.tranon.2021.101153_bib0074","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.virol.2014.12.033","article-title":"T cell exhaustion during persistent viral infections","volume":"479\u2013480","author":"Kahan","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.tranon.2021.101153_bib0075","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1089\/vim.2016.0057","article-title":"T cell distribution in relation to HIV\/HBV\/HCV coinfections and intravenous drug use","volume":"29","author":"Kallas","year":"2016","journal-title":"Viral. Immunol."},{"key":"10.1016\/j.tranon.2021.101153_bib0076","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1038\/ni1515","article-title":"Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction","volume":"8","author":"Kaufmann","year":"2007","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.tranon.2021.101153_bib0077","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.tranon.2021.101153_bib0078","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/cid\/cir207","article-title":"Immunodeficiency as a risk factor for non-AIDS-defining malignancies in HIV-1-infected patients receiving combination antiretroviral therapy","volume":"52","author":"Kesselring","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tranon.2021.101153_bib0079","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.4143\/crt.2015.278","article-title":"Real life experience of sorafenib treatment for hepatocellular carcinoma in Korea: from GIDEON data","volume":"48","author":"Kim","year":"2016","journal-title":"Cancer. Res. Treat."},{"key":"10.1016\/j.tranon.2021.101153_bib0080","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2017.73.7916","article-title":"Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and friends of cancer research joint research statement","volume":"35","author":"Kim","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2021.101153_bib0081","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.cell.2015.08.052","article-title":"Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth","volume":"162","author":"Kleffel","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.tranon.2021.101153_bib0082","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/ni1241","article-title":"T cells and viral persistence: lessons from diverse infections","volume":"6","author":"Klenerman","year":"2005","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.tranon.2021.101153_bib0083","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1093\/infdis\/jiw372","article-title":"During hepatitis C virus (HCV) infection and HCV-HIV coinfection, an elevated plasma level of autotaxin is associated with lysophosphatidic acid and markers of immune activation that normalize during interferon-free HCV therapy","volume":"214","author":"Kostadinova","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.tranon.2021.101153_bib0084","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"A randomised phase 3 trial of lenvatinib versus sorafenib in firstline treatment of patients with unresectable hepatocellular carcinoma","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.tranon.2021.101153_bib0085","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/hep.21361","article-title":"Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype","volume":"44","author":"Lankisch","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.tranon.2021.101153_bib0086","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T-cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat Immunol."},{"key":"10.1016\/j.tranon.2021.101153_bib0087","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/gutjnl-2014-306842","article-title":"Pathobiology of liver fibrosis: a translational success story","volume":"64","author":"Lee","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.tranon.2021.101153_bib0088","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1097\/QAD.0000000000001429","article-title":"Transient HIV-specific T cells increase and inflammation in an HIV-infected patient treated with nivolumab","volume":"31","author":"Le Garff","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.tranon.2021.101153_bib0089","first-page":"109","article-title":"Cytokine-mediated hepatic apoptosis","volume":"133","author":"Leist","year":"1998","journal-title":"Rev. Physiol. Biochem. Pharmacol."},{"key":"10.1016\/j.tranon.2021.101153_bib0090","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1111\/j.1742-1241.2010.02414.x","article-title":"Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study","volume":"64","author":"Lencioni","year":"2010","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.tranon.2021.101153_bib0091","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/ije\/dyh307","article-title":"Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS","volume":"34","author":"Lewden","year":"2005","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.tranon.2021.101153_bib0092","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1148\/radiol.2015141500","article-title":"Imaging features and prognosis of hepatocellular carcinoma in patients with cirrhosis who are coinfected with human immunodeficiency virus and hepatitis C virus","volume":"277","author":"Lewin","year":"2015","journal-title":"Radiology"},{"key":"10.1016\/j.tranon.2021.101153_bib0093","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/QAI.0b013e31826ebdc7","article-title":"Standardized care management ensures similar survival rates in HIV-positive and HIV-negative patients with hepatocellular carcinoma","volume":"61","author":"Lim","year":"2012","journal-title":"J. Acquir. Immune. Defic. Syndr."},{"issue":"6","key":"10.1016\/j.tranon.2021.101153_bib0094","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/QAD.0b013e32802ef30c","article-title":"Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy.","volume":"21","author":"Lima","year":"2007","journal-title":"Aids"},{"key":"10.1016\/j.tranon.2021.101153_bib0095","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1074\/jbc.M110.168286","article-title":"HIV and HCV cooperatively promote hepatic fibrogenesis via induction of reactive oxygen species and NF kappa B","volume":"286","author":"Lin","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tranon.2021.101153_bib0096","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2021.101153_bib0097","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s10637-016-0405-0","article-title":"Safety of raltegravir-based antiretroviral therapy in HIV-infected patients receiving multi-kinase inhibitors","volume":"35","author":"Loulergue","year":"2017","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.tranon.2021.101153_bib0098","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/lci2.15","article-title":"Regorafenib therapy for hepatocellular carcinoma in a HIV-1-infected patient: a case report","volume":"1","author":"Lythgoe","year":"2020","journal-title":"Liver Cancer Int."},{"key":"10.1016\/j.tranon.2021.101153_bib0099","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jhep.2007.09.010","article-title":"Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption","volume":"48","author":"Marcellin","year":"2008","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tranon.2021.101153_bib0100","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.jhep.2016.07.020","article-title":"Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: the GIDEON study","volume":"65","author":"Marrero","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tranon.2021.101153_bib0101","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1089\/08892220152644160","article-title":"Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients","volume":"17","author":"Mart\u00edn-Carbonero","year":"2001","journal-title":"AIDS. Res. Hum. Retroviruses."},{"key":"10.1016\/j.tranon.2021.101153_bib0102","doi-asserted-by":"crossref","first-page":"8056","DOI":"10.1128\/jvi.68.12.8056-8063.1994","article-title":"CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection","volume":"68","author":"Matloubian","year":"1994","journal-title":"J. Virol."},{"key":"10.1016\/j.tranon.2021.101153_bib0103","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.3748\/wjg.14.1657","article-title":"Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era","volume":"14","author":"MacDonald","year":"2008","journal-title":"World. J. Gastroenterol."},{"key":"10.1016\/j.tranon.2021.101153_bib0104","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","article-title":"CD8 T cell exhaustion during chronic viral infection and cancer","volume":"37","author":"McLane","year":"2019","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.tranon.2021.101153_bib0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2018.09.031","article-title":"Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysis","volume":"105","author":"McNamara","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.tranon.2021.101153_bib0106","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/QAD.0000000000001293","article-title":"Real-life experience with sorafenib for the treatment of hepatocellular carcinoma in HIV-infected patients","volume":"31","author":"Merchante","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.tranon.2021.101153_bib0107","first-page":"2380","article-title":"Smoothened is a master regulator of adult liver repair","volume":"123","author":"Michelotti","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tranon.2021.101153_bib0108","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1200\/JCO.2008.20.0931","article-title":"Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301","volume":"27","author":"Miller","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2021.101153_bib0109","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(07)60948-9","article-title":"Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study","volume":"370","author":"Mocroft","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.tranon.2021.101153_bib0110","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1200\/JCO.2011.41.4193","article-title":"HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era","volume":"30","author":"Montoto","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2021.101153_bib0111","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/362758a0","article-title":"Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells","volume":"362","author":"Moskophidis","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.tranon.2021.101153_bib0112","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.virusres.2011.01.001","article-title":"The X protein of HBV induces HIV-1 long terminal repeat transcription by enhancing the binding of C\/EBPbeta and CREB1\/2 regulatory proteins to the long terminal repeat of HIV-1","volume":"156","author":"Mu","year":"2011","journal-title":"Virus. Res."},{"key":"10.1016\/j.tranon.2021.101153_bib0113","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/sj.icb.7100015","article-title":"Acutely dysregulated, chronically disabled by the enemy within: t-cell responses to HIV-1 infection","volume":"85","author":"Munier","year":"2007","journal-title":"Immunol. Cell. Biol."},{"key":"10.1016\/j.tranon.2021.101153_bib0114","series-title":"NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers v.2","year":"2010"},{"key":"10.1016\/j.tranon.2021.101153_bib0115","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1200\/JCO.2014.55.8437","article-title":"Risk of incremental toxicities and associated costs of new anticancer drugs: a meta-analysis","volume":"32","author":"Niraula","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2021.101153_bib0116","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1756-9966-27-3","article-title":"HIV-1 Tat and AIDS associated cancer: targeting the cellular anti-cancer barrier","volume":"27","author":"Nunnari","year":"2008","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2021.101153_bib0117","unstructured":"OPDIVO (nivolumab) prescribing information. Silver spring, MD: food and drug administration (https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125554s055lbl.pdf) 2021."},{"key":"10.1016\/j.tranon.2021.101153_bib0118","first-page":"161","article-title":"Suspected interaction between sorafenib and HAART in an HIV-1 infected patient: a case report","volume":"58","author":"Ozenne","year":"2011","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.tranon.2021.101153_bib0119","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/COH.0b013e32834bbc71","article-title":"HIV and hepatitis C coinfection: pathogenesis and microbial translocation","volume":"6","author":"Page","year":"2011","journal-title":"Curr. Opin. HIV. AIDS."},{"key":"10.1016\/j.tranon.2021.101153_bib0120","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/nm.2395","article-title":"Low levels of SIV infection in sooty mangabey central memory CD4+ T cells are associated with limited ccr5 expression.","volume":"17","author":"Paiardini","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.tranon.2021.101153_bib0121","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators","volume":"338","author":"Palella","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2021.101153_bib0122","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.it.2015.02.008","article-title":"Overcoming T cell exhaustion in infection and cancer","volume":"36","author":"Pauken","year":"2015","journal-title":"Trends Immunol."},{"key":"10.1016\/j.tranon.2021.101153_bib0123","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1634\/theoncologist.2010-0010","article-title":"Sorafenib therapy for hepatocellular carcinoma in an HIV-HCV coinfected patient. A case report","volume":"15","author":"Perboni","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.tranon.2021.101153_bib0124","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1200\/JCO.2007.14.5532","article-title":"Including persons with HIV infection in cancer clinical trials","volume":"26","author":"Persad","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2021.101153_bib0125","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1084\/jem.20061496","article-title":"PD-1 is a regulator of virus specific CD8+ T cell survival in HIV infection","volume":"203","author":"Petrovas","year":"2006","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.tranon.2021.101153_bib0126","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jhep.2016.09.008","article-title":"The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma","volume":"66","author":"Pinato","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tranon.2021.101153_bib0127","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/QAD.0000000000001422","article-title":"Hepatocellular carcinoma: an evolving challenge in viral hepatitis and HIV coinfection","volume":"31","author":"Pinato","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.tranon.2021.101153_bib0128","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1200\/JCO.18.00885","article-title":"Influence of HIV infection on the natural history of hepatocellular carcinoma: results from a global multicohort study","volume":"37","author":"Pinato","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2021.101153_bib0129","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1634\/theoncologist.2008-0191","article-title":"Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis","volume":"14","author":"Pinter","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.tranon.2021.101153_bib0130","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1056\/NEJM200103293441307","article-title":"Interactions among drugs for HIV and opportunistic infections","volume":"344","author":"Piscitelli","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2021.101153_bib0131","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/CAD.0b013e32831fb500","article-title":"Sorafenib tosylate in advanced kidney cancer: past, present and future","volume":"20","author":"Porta","year":"2009","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.tranon.2021.101153_bib0132","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/00002030-200411190-00009","article-title":"Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome","volume":"18","author":"Puoti","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.tranon.2021.101153_bib0133","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2016.12.003","article-title":"Incidence and progression to cirrhosis of new HCV infections in persons living with HIV","volume":"23","author":"Puoti","year":"2017","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.tranon.2021.101153_bib0134","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/nm.2232","article-title":"Transcriptional analysis of HIV-specific CD8(+) T cells shows that PD-1 inhibits T-cell function by upregulating BATF","volume":"16","author":"Quigley","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.tranon.2021.101153_bib0135","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1128\/JVI.02021-06","article-title":"Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression","volume":"81","author":"Radziewicz","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.tranon.2021.101153_bib0136","doi-asserted-by":"crossref","first-page":"5499","DOI":"10.1128\/MCB.01080-06","article-title":"The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress","volume":"27","author":"Rahmani","year":"2007","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.tranon.2021.101153_bib0137","doi-asserted-by":"crossref","first-page":"e26331","DOI":"10.1371\/journal.pone.0026331","article-title":"Effects of sorafenib on intratumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948)","volume":"7","author":"Raut","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.tranon.2021.101153_bib0138","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","article-title":"Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy","volume":"65","author":"Reig","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tranon.2021.101153_bib0139","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jhep.2020.11.026","article-title":"Systemic treatment of HCC in special populations","volume":"74","author":"Rimassa","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tranon.2021.101153_bib0140","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.2217\/fon-2020-0669","article-title":"Systemic adjuvant treatment in hepatocellular carcinoma: tempted to do something rather than nothing","volume":"16","author":"Rizzo","year":"2020","journal-title":"Future Oncol"},{"key":"10.1016\/j.tranon.2021.101153_bib0141","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/hiv.12204","article-title":"Liver-related deaths in HIV-infected patients between 1995 and 2010 in France: the Mortavic 2010 study in collaboration with the Agence Nationale de Recherche sur le SIDA (ANRS) EN 20 Mortalite\u00b4 2010 survey","volume":"16","author":"Rosenthal","year":"2015","journal-title":"HIV. Med."},{"key":"10.1016\/j.tranon.2021.101153_bib0142","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1086\/466531","article-title":"Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia","volume":"192","author":"Rotger","year":"2005","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.tranon.2021.101153_bib0143","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S1470-2045(11)70056-0","article-title":"Use of antineoplastic agents in cancer patients with HIV\/AIDS","volume":"12","author":"Rudek","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tranon.2021.101153_bib0144","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/cncr.28554","article-title":"A phase 1\/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061","volume":"120","author":"Rudek","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.tranon.2021.101153_bib0145","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.jhep.2005.01.022","article-title":"Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol","volume":"42","author":"Salmon-Ceron","year":"2005","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tranon.2021.101153_bib0146","series-title":"International Aids Society Conference","article-title":"Immunovirological evolution in HIV infected patients treated with anti-PD-1 therapy","author":"Samri","year":"2017"},{"key":"10.1016\/j.tranon.2021.101153_bib0147","doi-asserted-by":"crossref","DOI":"10.1084\/jem.179.3.961","article-title":"The expression of the interleukin 6 gene induced by the human immunodeficiency virus type 1 Tat protein","volume":"179","author":"Scala","year":"1994","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.tranon.2021.101153_bib0148","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/jac\/dkp152","article-title":"Antiretroviral drug interactions: often unrecognized, frequently unavoidable, sometimes unmanageable","volume":"64","author":"Seden","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.tranon.2021.101153_bib0149","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1053\/j.gastro.2015.03.004","article-title":"Successful interferon-free therapy of chronic hepatitis C virus infection normalizes natural killer cell function","volume":"149","author":"Serti","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tranon.2021.101153_bib0150","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.immuni.2008.04.018","article-title":"Selective CD4+ T-cell help for antibody responses to a large viral pathogen: deterministic linkage of specificities","volume":"28","author":"Sette","year":"2008","journal-title":"Immunity"},{"issue":"9939","key":"10.1016\/j.tranon.2021.101153_bib0151","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0140-6736(14)60604-8","article-title":"Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration","volume":"384","author":"Smith","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.tranon.2021.101153_bib0152","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1158\/1078-0432.CCR-12-2063","article-title":"Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer","volume":"19","author":"Sznol","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2021.101153_bib0153","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/QAD.0b013e3282f2dbe7","article-title":"Immune activation and AIDS pathogenesis","volume":"22","author":"Sodora","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.tranon.2021.101153_bib0154","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.jhep.2014.12.009","article-title":"Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors","volume":"62","author":"Sohn","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tranon.2021.101153_bib0155","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/annonc\/mdv606","article-title":"Non-AIDS-related malignancies: expert consensus review and practical applications from the multidisciplinary CANCERVIH working group.","volume":"27","author":"Spano","year":"2016","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.tranon.2021.101153_bib0156","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2217\/14622416.9.6.703","article-title":"Pharmacogenetics of Gilbert's syndrome","volume":"9","author":"Strassburg","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.tranon.2021.101153_bib0157","first-page":"6501","article-title":"B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma","volume":"63","author":"Strome","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2021.101153_bib0158","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S1089-3261(02)00074-0","article-title":"Hepatitis C in the HIV-infected patient","volume":"7","author":"Sulkowski","year":"2003","journal-title":"Clin. Liver. Dis."},{"key":"10.1016\/j.tranon.2021.101153_bib0159","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.jhep.2011.01.047","article-title":"Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma","volume":"55","author":"Tai","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tranon.2021.101153_bib0160","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/mc.20240","article-title":"Roles of reactive oxygen species in hepatocarcinogenesis and drug resistance gene expression in liver cancers","volume":"45","author":"Tien Kuo","year":"2006","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.tranon.2021.101153_bib0161","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.coi.2011.12.009","article-title":"Targeting the PD-1\/B7-H1(PD-L1) pathway to activate anti-tumor immunity","volume":"24","author":"Topalian","year":"2012","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.tranon.2021.101153_bib0162","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/nm1482","article-title":"Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction","volume":"12","author":"Trautmann","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.tranon.2021.101153_bib0163","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/hep.23679","article-title":"Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: implications for the pathogenesis of HIV\/hepatitis C virus-induced liver fibrosis","volume":"52","author":"Tuyama","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.tranon.2021.101153_bib0164","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1182\/blood-2014-08-551598","article-title":"How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus","volume":"125","author":"Uldrick","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2021.101153_bib0165","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.1200\/JCO.2017.73.7338","article-title":"Modernizing clinical trial eligibility criteria: recommendations of the American Society of Clinical Oncology-Friends of Cancer Research HIV Working Group.","volume":"35","author":"Uldrick","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2021.101153_bib0166","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jamaoncol.2019.2244","article-title":"Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer-A phase 1 study","volume":"5","author":"Uldrick","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.tranon.2021.101153_bib0167","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/jcp.21753","article-title":"Role of RAF\/MEK\/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines","volume":"220","author":"Ulivi","year":"2009","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.tranon.2021.101153_bib0168","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/nature07662","article-title":"Enhancing SIV-specific immunity in vivo by PD-1 blockade","volume":"458","author":"Velu","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.tranon.2021.101153_bib0169","doi-asserted-by":"crossref","first-page":"11398","DOI":"10.1128\/JVI.01177-06","article-title":"PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion","volume":"80","author":"Urbani","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.tranon.2021.101153_bib0170","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006438","article-title":"Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism.","volume":"5","author":"Vujkovic-Cvijin","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.tranon.2021.101153_bib0171","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1468-1293.2012.01051.x","article-title":"Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study","volume":"14","author":"Weber","year":"2013","journal-title":"HIV. Med."},{"key":"10.1016\/j.tranon.2021.101153_bib0172","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1128\/jvi.68.7.4177-4185.1994","article-title":"Human immunodeficiency virus type 1 upregulates interleukin secretion in activated T cells","volume":"68","author":"Westendorp","year":"1994","journal-title":"J. Virol."},{"key":"10.1016\/j.tranon.2021.101153_bib0173","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.immuni.2007.09.006","article-title":"Molecular signature of CD8+ T cell exhaustion during chronic viral infection","volume":"27","author":"Wherry","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.tranon.2021.101153_bib0174","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.tranon.2021.101153_bib0175","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/QAD.0000000000000562","article-title":"Effect of ipilimumab on the HIV reservoir in an HIV-infected individual with metastatic melanoma","volume":"29","author":"Wightman","year":"2015","journal-title":"AIDS"},{"key":"10.1016\/j.tranon.2021.101153_bib0176","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrgastro.2013.149","article-title":"From NAFLD to NASH to cirrhosis-new insights into disease mechanisms","volume":"10","author":"Wree","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tranon.2021.101153_bib0177","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.canlet.2013.08.035","article-title":"Hepatitis B virus-induced hepatocellular carcinoma.","volume":"345","author":"Xu","year":"2014","journal-title":"Cancer. Lett."},{"key":"10.1016\/j.tranon.2021.101153_bib0178","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1084\/jem.188.12.2205","article-title":"Viral immune evasion due to persistence of activated T cells without effector function","volume":"188","author":"Zajac","year":"1998","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.tranon.2021.101153_bib0179","doi-asserted-by":"crossref","first-page":"722","DOI":"10.3389\/fphar.2020.00722","article-title":"PD-1\/PD-L1 Based Combinational Cancer Therapy: icing on the Cake","volume":"11","author":"Zhang","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.tranon.2021.101153_bib0180","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1158\/1078-0432.CCR-15-1849","article-title":"Reversing T-cell dysfunction and exhaustion in cancer","volume":"22","author":"Zarour","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2021.101153_bib0181","first-page":"4481","article-title":"Human immunodeficiency virus type 1 Tat protein protects lymphoid, epithelial, and neuronal cell lines from death by apoptosis","volume":"53","author":"Zauli","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.tranon.2021.101153_bib0182","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.tranon.2021.101153_bib0183","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.tranon.2021.101153_bib0184","doi-asserted-by":"crossref","first-page":"10355","DOI":"10.1074\/jbc.M111.312751","article-title":"Hepatic stellate cell-derived delta-like homolog 1 (DLK1) protein in liver regeneration.","volume":"287","author":"Zhu","year":"2012","journal-title":"J. Biol. Chem."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523321001455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523321001455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:19:00Z","timestamp":1761844740000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523321001455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":184,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S1936523321001455"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2021.101153","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatocellular cancer therapy in patients with HIV infection: Disparities in cancer care, trials enrolment, and cancer-related research","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2021.101153","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101153"}}